(Total Views: 370)
Posted On: 05/04/2017 8:20:45 AM
Post# of 23059
$SGMO
The leader in therapeutic genome editing, announced today that the Company has received notice from the U.S. Food and Drug Administration ( FDA ) of special regulatory designations for three of the Company's clinical programs.
The FDA has granted orphan drug status for SB-525 cDNA gene therapy for Hemophilia A.
There's also fast track designation for SB-FIX in vivo genome editing treatment for Hemophilia B, and Rare Pediatric Disease designation for SB-913 in vivo genome editing treatment for Mucopolysaccharidosis Type II (MPS II).
The leader in therapeutic genome editing, announced today that the Company has received notice from the U.S. Food and Drug Administration ( FDA ) of special regulatory designations for three of the Company's clinical programs.
The FDA has granted orphan drug status for SB-525 cDNA gene therapy for Hemophilia A.
There's also fast track designation for SB-FIX in vivo genome editing treatment for Hemophilia B, and Rare Pediatric Disease designation for SB-913 in vivo genome editing treatment for Mucopolysaccharidosis Type II (MPS II).
(1)
(0)
Nothing I state is intended to be a recommendation to buy or sell, opinion only. Readers are solely responsible for how they use the information.
